Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Disease Models & Mechanisms|September 19, 2013
The emerging use of zebrafish to model metabolic diseaseAsha Seth, Derek L Stemple, Inês Barroso
Neuroendocrinology|March 8, 2003
Effects of galanin-like peptide on food intake and the hypothalamo-pituitary-thyroid axisAsha Seth, Sarah Stanley, Waljit Dhillo, et al.
Endocrinology|October 25, 2003
Galanin-like peptide stimulates the release of gonadotropin-releasing hormone in vitro and may mediate the effects of leptin on the hypothalamo-pituitary-gonadal axisAsha Seth, Sarah Stanley, Preeti Jethwa, et al.
Molecular Endocrinology (Baltimore, Md.)|August 9, 2007
The nuclear receptor cofactor, receptor-interacting protein 140, is required for the regulation of hepatic lipid and glucose metabolism by liver X receptorBirger Herzog, Magnus Hallberg, Asha Seth, et al.
FEBS Letters|November 21, 2007
Role of RIP140 in metabolic tissues: connections to diseaseRoger White, Daniel Morganstein, Mark Christian, et al.
Molecular Endocrinology (Baltimore, Md.)|April 26, 2007
Receptor interacting protein 140 regulates expression of uncoupling protein 1 in adipocytes through specific peroxisome proliferator activated receptor isoforms and estrogen-related receptor alphaDarja Debevec, Mark Christian, Daniel Morganstein, et al.
American Journal of Physiology. Endocrinology and Metabolism|October 22, 2002
Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed ratsCatherine L Dakin, Caroline J Small, Adrian J Park, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 6, 2003
A role for arcuate cocaine and amphetamine-regulated transcript in hyperphagia, thermogenesis, and cold adaptationWing May Kong, Sarah Stanley, James Gardiner, et al.
Pharmaceutics|March 26, 2022
Injectable Biodegradable Silica Depot: Two Months of Sustained Release of the Blood Glucose Lowering Peptide, PramlintidePuneet Tyagi, Mika Koskinen, Jari Mikkola, et al.
The Biochemical Journal|July 17, 2016
Use of CRISPR/Cas9-engineered INS-1 pancreatic β cells to define the pharmacology of dual GIPR/GLP-1R agonistsJacqueline Naylor, Arthur T Suckow, Asha Seth, et al.
Pageof 2